Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Gains from Sales and Divestitures: 2023-2024

Historic Gains from Sales and Divestitures for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $122,034.

  • Monte Rosa Therapeutics' Gains from Sales and Divestitures fell 8.09% to $112,159 in Q3 2025 from the same period last year, while for Sep 2025 it was $112,159, marking a year-over-year decrease of 8.09%. This contributed to the annual value of $122,034 for FY2024, which is 19.81% up from last year.
  • Monte Rosa Therapeutics' Gains from Sales and Divestitures amounted to $122,034 in FY2024, which was up 19.81% from $101,855 recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Gains from Sales and Divestitures registered a high of $122,034 during FY2024, and its lowest value of $101,855 during FY2023.
  • Over the past 2 years, Monte Rosa Therapeutics' median Gains from Sales and Divestitures value was $111,944 (recorded in 2023), while the average stood at $111,944.
  • Data for Monte Rosa Therapeutics' Gains from Sales and Divestitures shows a peak YoY increased of 19.81% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Gains from Sales and Divestitures (Yearly) stood at $101,855 in 2023, then grew by 19.81% to $122,034 in 2024.